MX2023008573A - Modulador de via, composicion farmaceutica que tiene la misma, uso y metodo terapeutico que utiliza la misma. - Google Patents

Modulador de via, composicion farmaceutica que tiene la misma, uso y metodo terapeutico que utiliza la misma.

Info

Publication number
MX2023008573A
MX2023008573A MX2023008573A MX2023008573A MX2023008573A MX 2023008573 A MX2023008573 A MX 2023008573A MX 2023008573 A MX2023008573 A MX 2023008573A MX 2023008573 A MX2023008573 A MX 2023008573A MX 2023008573 A MX2023008573 A MX 2023008573A
Authority
MX
Mexico
Prior art keywords
same
pharmaceutical composition
pathway modulator
therapeutic method
autoimmune diseases
Prior art date
Application number
MX2023008573A
Other languages
English (en)
Inventor
Yu Chen
Yijun Deng
Ke Pan
Qiaoling Sun
Jing Lv
Original Assignee
Jiangsu Yahong Meditech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Yahong Meditech Co Ltd filed Critical Jiangsu Yahong Meditech Co Ltd
Publication of MX2023008573A publication Critical patent/MX2023008573A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un modulador de vía, una composición farmacéutica que lo tiene, su uso y un método terapéutico que lo usa. El modulador de la vía (que comprende uno o más de un inhibidor de la dopamina ß-hidroxilasa, un agonista del receptor y un antagonista del receptor) puede inhibir el desarrollo de enfermedades autoinmunes mediante inmunorregulación, lo que proporciona fármacos terapéuticos potenciales para el tratamiento de enfermedades autoinmunes.
MX2023008573A 2021-01-26 2022-01-25 Modulador de via, composicion farmaceutica que tiene la misma, uso y metodo terapeutico que utiliza la misma. MX2023008573A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110103435 2021-01-26
PCT/CN2022/073849 WO2022161364A1 (zh) 2021-01-26 2022-01-25 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法

Publications (1)

Publication Number Publication Date
MX2023008573A true MX2023008573A (es) 2023-08-08

Family

ID=82654172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008573A MX2023008573A (es) 2021-01-26 2022-01-25 Modulador de via, composicion farmaceutica que tiene la misma, uso y metodo terapeutico que utiliza la misma.

Country Status (9)

Country Link
EP (1) EP4285898A1 (es)
JP (1) JP2024503906A (es)
KR (1) KR20230137374A (es)
CN (1) CN116490177A (es)
AU (1) AU2022213938A1 (es)
CA (1) CA3205182A1 (es)
MX (1) MX2023008573A (es)
TW (1) TW202241415A (es)
WO (1) WO2022161364A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2581556B2 (ja) 1986-05-06 1997-02-12 メレルダウファーマスーティカルズ インコーポレーテッド 新規なドパミンベ−タヒドロキシラ−ゼ抑制剤
WO1995029165A2 (en) 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors
CA3007641C (en) * 2015-12-09 2023-10-17 Brandeis University Dbh inhibitors for treating or preventing memory loss
EP3490554B1 (en) * 2016-07-28 2023-07-05 Jiangsu Yahong Meditech Co., Ltd. Uses of dopamine beta-hydroxylase (dbh) inhibitors for the treatment of cancer
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation

Also Published As

Publication number Publication date
WO2022161364A1 (zh) 2022-08-04
CN116490177A (zh) 2023-07-25
JP2024503906A (ja) 2024-01-29
AU2022213938A1 (en) 2023-09-07
KR20230137374A (ko) 2023-10-04
TW202241415A (zh) 2022-11-01
EP4285898A1 (en) 2023-12-06
CA3205182A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
MX2021009037A (es) Composiciones y metodos para el manejo de trastornos.
Pergolizzi et al. The pharmacological management of dental pain
AU2007211091A8 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
NO20071175L (no) Sammensetning for langvarig medikamentfrigivning som viser et okende null-bestillende frigivningsmonster, fremgangsmate for fremstilling av en slik sammensetning
CL2008002051A1 (es) Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas.
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
MX2021010759A (es) Regimen de dosificacion para un agonista de los receptores de s1p.
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
MX2019011904A (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos.
CL2021003017S1 (es) Porción de dispositivo para administración de dosis. (divisional solicitud 200003174)
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
CO5261535A1 (es) Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
MX2020003088A (es) Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina.
Greene Chronic pain: pathophysiology and treatment implications
MX2021008650A (es) Compuestos heterociclicos como antagonistas de adenosina.
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
AU2018333954A1 (en) Methods and compositions to inhibit dependence on opioids
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
CL2021001528A1 (es) Formulaciones farmacéuticas que contienen relacorilant, un compuesto heteroaril-cetona azadecalina fusionada.
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
PH12021550549A1 (en) Dp antagonist
MX2023008573A (es) Modulador de via, composicion farmaceutica que tiene la misma, uso y metodo terapeutico que utiliza la misma.
Grazio et al. Smjernice za liječenje bolesnika s osteoartritisom kuka i/ili koljena
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica